Synta chief Bahcall makes an abrupt exit; London refugee Xenetic opens facility in Lexington, MA; Acadia raising $150M;

@FierceBiotech: Theravance bets it can innovate without GlaxoSmithKline as spinoff nears. Story | Follow @FierceBiotech

@JohnCFierce: The coming Zohydro addiction issue is a natural mainstream media piece--sets the FDA up for a big black eye with more to come. Story via CBS | Follow @JohnCFierce

@DamianFierce: On his farewell tour, Roche Chairman Franz Humer says Roche is poised for some dealmaking. News | Follow @DamianFierce

@EmilyMFierce: BioCryst compound prevents Marburg virus in monkeys. Article | Follow @EmilyMFierce

> Shares of Synta Pharmaceuticals ($SNTA) are down 5% this morning on the news that CEO and cofounder Safi Bahcall resigned suddenly. The biotech's shares are down by about half since it became apparent earlier this year that its lead drug, ganetespib, was less effective than analysts had expected to see. Report

> Xenetic Biosciences is celebrating the opening of its new HQ and R&D facility in Lexington, MA. The biotech moved to Massachusetts from London and currently has 7 staffers in place with plans to add 7 more by the end of this year. Release

> Acadia Pharmaceuticals ($ACAD) is raising $150 million from the sale of stock. Release

> Boehringer Ingelheim produced positive Phase III data on the use of Spiriva with its Respimat inhaler for asthma. Story

Medical Device News

@FierceMedDev: Mindray, a giant Chinese medical device company, has just expanded an already impressive share repurchase program. More | Follow @FierceMedDev

@MarkHFierce: Google Glass is showing some promise as a medical diagnostic tool. Cool stuff, with pictures. Story | Follow @MarkHFierce

@MichaelGFierce: New manufacturing technique offers tailored delivery nanoparticles made of iron, silver and silicon. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Researchers created custom-fitting heart sacs that could help with treatment. Article | Follow @EmilyWFierce

> Invuity brings a new $36M in growth equity to the surgical tools market. News

> Germany's Biotronik wins a CE mark for a super-tiny, MRI-safe CRT lead. Story

> Oxford Immunotec reports narrowed loss, Asia growth in first earnings post-IPO. Report

Pharma News

@FiercePharma: As in...right now. The top 10 pharma companies by 2013 revenue report is live on the FP site. Report | Follow @FiercePharma

@TracyStaton: This year's version of FiercePharma's most popular special report: The top 10 pharma companies by 2013 revenue. More | Follow @TracyStaton

@EricPFierce: WSJ says Pfizer angling for OTC Lipitor. That will get generic drugmakers' notice. Story | Follow @EricPFierce

@CarlyHFierce: New report, now live: The top 10 pharma companies by 2013 revenue. Report | Follow @CarlyHFierce

> Takeda fesses up to improperly marketing its blood-pressure blockbuster, Blopress. Article

> Sanofi slapped with €28M bribery fine for former German employees' scheme. Piece

> Lilly, Pfizer and Merck slash doctor payments, but J&J and Forest shell out more. More

Biotech Research News

> HIV immune discovery could lay the groundwork for a vaccine. Story

> Experimental supplement extends lifespan, stops metabolic disease in mice. Article

> BioCryst compound prevents Marburg virus in monkeys. News

> New anti-inflammatory molecule could provide a model for new drug design. Article

> Brain cell communication plays role in regulating Alzheimer's protein. Story

> NIH makes new database on age-related diseases available to researchers. Brief

Pharma Manufacturing News

Regeneron preparing for a plant expansion and a fill-finish facility in Ireland. Story

> Jubilant says the FDA has cleared its Canada plant. News

> Fresenius to build new plant in Australia. Story

> Lilly invests in its Brazilian packaging plant. Article

> Drug purchasing group wants drugmakers to work with GPOs on shortages. Story

> Pharma packaging market is forecast to hit $90 billion in 2017. Brief

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.